Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 81

Sort by

Sort Order Select

Journal Articles

Single-Cell Roadmap of Immune Cell Response in Chronic Myeloid Leukemia

Jani Huuhtanen, Jason Theodoropoulos, BSc, Rebecca Warfvinge, MSc, Andreas Burchert, MD, Tiina Kasanen, Jay Klievink, MSc, Shady Adnan Awad, MD, Olli Dufva, MD, Mette Ilander, PhD, Taina Jaatinen, Ulla Olsson-Strömberg, MD PhD, Henrik Hjorth-Hansen, MD, Göran Karlsson, PhD, Harri Lähdesmäki, PhD, Anna Kreutzman, PhD, Satu Mustjoki, MD PhD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-139134

Published: 2020

Journal Articles

Heterogeneity of Molecular Mechanisms Determining Blood Cancer Cell Lines Resistance to Natural Killer Cells in the Context of Tumor-Stromal Interactions: Insights from Studies of Pooled "DNA-Barcoded" Cell Line Panels

Sara Gandolfi, MD, Michal Sheffer, PhD, Olli Dufva, Khalid Saeed, Emily Lowry, Olga Dashevsky, PhD, Ryosuke Shirasaki, MD PhD, Ricardo De Matos Simoes, PhD, Jennifer Roth, Rizwan Romee, MD PhD, Satu Mustjoki, MD PhD, Constantine S. Mitsiades, MD PhD

Blood (2019) 134 (Supplement_1): 620.

https://doi.org/10.1182/blood-2019-130793

Published: 2019

Journal Articles

CRISPR Screens Identify Mechanisms of Natural Killer Cell Evasion across Blood Cancers

Olli Dufva, Khalid Saeed, Sara Gandolfi, MD, Michal Sheffer, PhD, Jay Klievink, Petri Pölönen, MSc, Tiina Hannunen, Mette Ilander, PhD, Pekka Ellonen, BSc, Matti Kankainen, PhD, Dean Anthony Lee, MD PhD, Constantine S. Mitsiades, MD PhD, Satu Mustjoki, MD PhD

Blood (2019) 134 (Supplement_1): 3597.

https://doi.org/10.1182/blood-2019-129837

Published: 2019

Journal Articles

Genotypes of the Gene Encoding the Membrane Transporter SLC22A4 Are Associated with Molecular Relapse-Free Survival after Discontinuation of Imatinib Therapy in Patients with Chronic Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 1647.

https://doi.org/10.1182/blood-2019-129710

Published: 2019

Journal Articles

T Cell Landscape of Immune Aplastic Anemia Reveals a Convergent Antigen-Specific Signature

Jani Huuhtanen, BMed, Sofie Lundgren, BMed, Mikko A Keränen, MD PhD, Xingmin Feng, PhD, Cassandra M Kerr, MS, Emmi Jokinen, MSc, Markus Heinonen, PhD, Paula Savola, MD PhD, Tiina Kelkka, PhD, Freja Ebeling, MD PhD, Georgina L Ryland, Lucy Fox, Piers Blombery, MBBS, Eva Hellstrom Lindberg, MD PhD, Neal S. Young, MD, Jaroslaw P. Maciejewski, MD PhD, Harri Lähdesmäki, PhD, Satu Mustjoki, MD PhD

Blood (2019) 134 (Supplement_1): 108.

https://doi.org/10.1182/blood-2019-127790

Published: 2019

Journal Articles

BCR-ABL1 p190 in CML: A Minor Breakpoint with a Major Impact

Shady Adnan Awad, MD, Helena Hohtari, MD, Komal Kumar Javarappa, PhD, Tania Brandstoetter, Daehong Kim, Swapnil Potdar, MSc, Caroline A Heckman, PhD, Soili Kytölä, PhD, Kimmo Porkka, Eszter Doma, PhD, Veronika Sexl, MD PhD, Matti Kankainen, PhD, Satu Mustjoki, MD PhD

Blood (2019) 134 (Supplement_1): 190.

https://doi.org/10.1182/blood-2019-126584

Published: 2019

Journal Articles

Targeting BCL-2, BCL-XL, BCL-W and MDM2 in B-Cell Acute Lymphoblastic Leukemia Is Highly Effective Ex Vivo

Helena Hohtari, MD, Shady Awad, MD, Olli Dufva, Swapnil Potdar, MSc, Caroline A Heckman, PhD, Krister Wennerberg, PhD, Satu Mustjoki, MD PhD, Kimmo Porkka, MD PhD

Blood (2018) 132 (Supplement 1): 3975.

https://doi.org/10.1182/blood-2018-99-110610

Published: 2018

Journal Articles

Immunogenomic Landscape of Hematological Malignancies

Olli Dufva, Petri Pölönen, MSc, Oscar Brück, MD, Mikko A Keränen, MD PhD, Juha Mehtonen, MSc, Sanna M. Siitonen, MD PhD, Suvi-Katri Leivonen, PhD, Leo Meriranta, MS, Sirpa Leppa, MD Prof, Matti Nykter, Olli Lohi, MD PhD, Merja Heinäniemi, PhD, Satu Mustjoki, MD PhD

Blood (2018) 132 (Supplement 1): 2596.

https://doi.org/10.1182/blood-2018-99-118335

Published: 2018

Journal Articles

Quantitative Multiplex Immunohistochemistry Identifies Immunosuppression in the AML Bone Marrow and NK-Cells As Prognostic Biomarker in Intermediate-Risk Patients

Oscar Brück, MD, Olli Dufva, Sami Blom, MSc, Riku Turkki, MSc, Mette Ilander, PhD, Sanna M. Siitonen, MD PhD, Panu Kovanen, MD PhD, Celine Pallaud, PhD, Pedro Marques Ramos, PhD, Hanna Lähteenmäki, Katja Välimäki, Antonio Ribeiro, BSc, Olli Kallioniemi, MD PhD, Kimmo Porkka, MD PhD, Teijo Pellinen, PhD, Satu Mustjoki, MD PhD

Blood (2018) 132 (Supplement 1): 2774.

https://doi.org/10.1182/blood-2018-99-116628

Published: 2018

Journal Articles

Genome-Scale CRISPR Screens Identify Essential Genes for Sensitivity to Natural Killer Cells in Hematological Malignancies

Olli Dufva, Jay Klievink, Khalid Saeed, Matti Kankainen, PhD, Mette Ilander, PhD, Tiina Hannunen, Sonja Lagström, Pekka Ellonen, BSc, Dean Anthony Lee, MD PhD, Satu Mustjoki, MD PhD

Blood (2018) 132 (Supplement 1): 732.

https://doi.org/10.1182/blood-2018-99-117985

Published: 2018

Journal Articles

RUNX1 Mutations Identify an Entity of Blast Phase Chronic Myeloid Leukemia (BP-CML) Patients with Distinct Phenotype, Transcriptional Profile and Drug Vulnerabilities

Shady Awad, MD, Matti Kankainen, PhD, Olli Dufva, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Satu Mustjoki, MD PhD

Blood (2018) 132 (Supplement 1): 4257.

https://doi.org/10.1182/blood-2018-99-111602

Published: 2018

Journal Articles

Health-Related Quality of Life Outcomes in Newly Diagnosed Chronic Myeloid Leukemia Patients Treated with Dasatinib and Low Dose Pegylated Interferon

Henrik Hjorth-Hansen, MD, Satu Mustjoki, MD PhD, Ulla Olsson-Strömberg, MD PhD, Jesper Stentoft, Professor, dr.MD, Fabio Efficace, PhD, Hemming Johansson, PhD, Yvonne Brandberg, PhD

Blood (2018) 132 (Supplement 1): 4260.

https://doi.org/10.1182/blood-2018-99-111714

Published: 2018

Journal Articles

Somatic Mutations in T Cells As Possible Regulators of Immunodeficiency

Paula Savola, MD, Timi Martelius, MD PhD, Matti Kankainen, PhD, Yrjö Koski, BTech, Samuli Eldfors, PhD, Jani Huuhtanen, BMed, Tiina Kelkka, PhD, Sofie Lundgren, BMed, Pekka Ellonen, BSc, Panu Kovanen, MD PhD, Soili Kytölä, PhD, Mikko Seppänen, MD PhD, Satu Mustjoki, MD PhD

Blood (2018) 132 (Supplement 1): 515.

https://doi.org/10.1182/blood-2018-99-110757

Published: 2018

Journal Articles

Extensive Immunosuppression in the Acute Myeloid Leukemia (AML) Bone Marrow and Discovery of NK Cells As Biomarker of Superior Survival

Oscar Brück, Sami Blom, MSc, Olli Dufva, BSc, Riku Turkki, MSc, Antonio Ribeiro, BSc, Sanna Siitonen, MD PhD, Panu Kovanen, MD PhD, Olli Kallioniemi, MD PhD, Kimmo Porkka, MD PhD, Teijo Pellinen, PhD, Satu Mustjoki, MD PhD

Blood (2017) 130 (Supplement 1): 3943.

https://doi.org/10.1182/blood.V130.Suppl_1.3943.3943

Published: 2017

Journal Articles

Cessation of Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response: Results of the Euro-Ski Trial

Blood (2016) 128 (22): 787.

https://doi.org/10.1182/blood.V128.22.787.787

Published: 2016

Journal Articles

No Differences in Molecular Relapse-Free Survival after Stopping Imatinib Treatment of Chronic Myeloid Leukemia Between Patients with Prior 4.5 Log Reduction (MR4.5) but Detectable and Patients with Undetectable Disease in the EURO-SKI Trial

Blood (2016) 128 (22): 789.

https://doi.org/10.1182/blood.V128.22.789.789

Published: 2016

Journal Articles

Early MRD-Negativity May Predict for Favorable Outcome Irrespective of Allotransplantation in TKI-Treated Patients with Ph-Positive Acute Lymphoblastic Leukemia

Helena Hohtari, MD, Marjatta Sinisalo, Tapio Nousiainen, MD PhD, Perttu Koskenvesa, MD, Ulla Wartiovaara-Kautto, MD PhD, Satu Mustjoki, MD PhD, Pirjo Koistinen, MD PhD, Marjaana Säily, MD PhD, Maija Itälä-Remes, Erkki Elonen, MD PhD, Kari Remes, MD PhD, Kimmo Porkka, MD PhD

Blood (2016) 128 (22): 1598.

https://doi.org/10.1182/blood.V128.22.1598.1598

Published: 2016

Journal Articles

Pan-Hematopoietic Cancer Gene Expression Analysis Identifies Immunologically Active Acute Myeloid Leukemia Subtypes

Olli Dufva, Petri Pölönen, Mikko A Keränen, MD PhD, Thomas Liuksiala, Jake Lin, Juha Mehtonen, MSc, Sergei Häyrynen, Kirsi Granberg, PhD, Matti Nykter, PhD, Olli Lohi, Merja Heinäniemi, PhD, Satu Mustjoki, MD PhD

Blood (2016) 128 (22): 1725.

https://doi.org/10.1182/blood.V128.22.1725.1725

Published: 2016

Journal Articles

A New Computational Method to Predict Long-Term Minimal Residual Disease and Molecular Relapse after TKI-Cessation in CML

Ingmar Glauche, PhD, Hendrik Liebscher, Christoph Baldow, Matthias Kuhn, Philipp Schulze, Tom Haehnel, Astghik Voskanyan, PhD, Joelle Guilhot, PhD, Stéphanie Dulucq, PhD, Nikolas von Bubnoff, MD, Susanne Saussele, MD, Satu Mustjoki, MD PhD, Philipp J. Jost, MD, Francois Guilhot, MD PhD, François-Xavier Mahon, MD PhD, Ingo Roeder, PhD

Blood (2016) 128 (22): 3099.

https://doi.org/10.1182/blood.V128.22.3099.3099

Published: 2016

Journal Articles

Molecular Characterization of Cytotoxic T Cell Repertoire in Aplastic Anemia and Myelodysplastic Syndromes

Sofie Alexandra Lundgren, MDPhDstudent, Mikko A Keränen, MD PhD, Paula Savola, MDPhDstudent, Giljun Park, MSc, PhD, Freja Ebeling, MD PhD, Gunilla Walldin, Eva Hellström-Lindsberg, Satu Mustjoki, MD PhD

Blood (2016) 128 (22): 3893.

https://doi.org/10.1182/blood.V128.22.3893.3893

Published: 2016

NARROW

Single-Cell Roadmap of Immune Cell Response in Chronic Myeloid Leukemia

Heterogeneity of Molecular Mechanisms Determining Blood Cancer Cell Lines Resistance to Natural Killer Cells in the Context of Tumor-Stromal Interactions: Insights from Studies of Pooled "DNA-Barcoded" Cell Line Panels

CRISPR Screens Identify Mechanisms of Natural Killer Cell Evasion across Blood Cancers

Genotypes of the Gene Encoding the Membrane Transporter SLC22A4 Are Associated with Molecular Relapse-Free Survival after Discontinuation of Imatinib Therapy in Patients with Chronic Myeloid Leukemia

T Cell Landscape of Immune Aplastic Anemia Reveals a Convergent Antigen-Specific Signature

BCR-ABL1 p190 in CML: A Minor Breakpoint with a Major Impact

Targeting BCL-2, BCL-XL, BCL-W and MDM2 in B-Cell Acute Lymphoblastic Leukemia Is Highly Effective Ex Vivo

Immunogenomic Landscape of Hematological Malignancies

Quantitative Multiplex Immunohistochemistry Identifies Immunosuppression in the AML Bone Marrow and NK-Cells As Prognostic Biomarker in Intermediate-Risk Patients

Genome-Scale CRISPR Screens Identify Essential Genes for Sensitivity to Natural Killer Cells in Hematological Malignancies

RUNX1 Mutations Identify an Entity of Blast Phase Chronic Myeloid Leukemia (BP-CML) Patients with Distinct Phenotype, Transcriptional Profile and Drug Vulnerabilities

Health-Related Quality of Life Outcomes in Newly Diagnosed Chronic Myeloid Leukemia Patients Treated with Dasatinib and Low Dose Pegylated Interferon

Somatic Mutations in T Cells As Possible Regulators of Immunodeficiency

Extensive Immunosuppression in the Acute Myeloid Leukemia (AML) Bone Marrow and Discovery of NK Cells As Biomarker of Superior Survival

Cessation of Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response: Results of the Euro-Ski Trial

No Differences in Molecular Relapse-Free Survival after Stopping Imatinib Treatment of Chronic Myeloid Leukemia Between Patients with Prior 4.5 Log Reduction (MR4.5) but Detectable and Patients with Undetectable Disease in the EURO-SKI Trial

Early MRD-Negativity May Predict for Favorable Outcome Irrespective of Allotransplantation in TKI-Treated Patients with Ph-Positive Acute Lymphoblastic Leukemia

Pan-Hematopoietic Cancer Gene Expression Analysis Identifies Immunologically Active Acute Myeloid Leukemia Subtypes

A New Computational Method to Predict Long-Term Minimal Residual Disease and Molecular Relapse after TKI-Cessation in CML

Molecular Characterization of Cytotoxic T Cell Repertoire in Aplastic Anemia and Myelodysplastic Syndromes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only